No Data
No Data
Bod Science Further Delays Filing of Half-Year Report
Bod Science (ASX:BOD) further delayed the filing of its report for the six months ended Dec. 31, 2023, to July 12 amid an ongoing review by auditor Nexia Sydney Audit, according to a Monday filing wit
Bod Science Announces Delay of Half-Year Report Lodgment
Cannabis-focused drug developer Bod Science (ASX:BOD) said the report for the half year ended Dec. 31, 2023 will be lodged with the Australian bourse by June 14. This was a further delay from the prev
Bod Science Announces Delay in Appendix 4D Lodgement
Bod Science (ASX:BOD) said its appendix 4D, or half-year report, for the six months ended Dec. 31, 2023, will be delayed anew following a rejection by the the Australian Securities and Investments Com
BOD Science Signs Supply Agreement in Medicinal Cannabis With Green Farmers
BOD Science (ASX:BOD) signed a supply agreement with licensed cultivator, importer, and genetic holder of medicinal cannabis, Green Farmers, according to a Wednesday release. BOD Science will supply a
Bod Science Receives AU$1.6 Million R&D Tax Refund; Shares Rise 8%
Bod Science (ASX:BOD) received a more than AU$1.6 million of research and development tax rebate for fiscal 2023. The rebate fully covers the outstanding AU$1.2 million loan payable to Radium Capital,
Bod Expects to Receive Funds From Antah Soon
Bod Science (ASX:BOD) provided an update on its capital raising program, saying it did not secure the AU$440,000 on Nov. 20, because of a delay in the receipt of funds from investor Antah Healthcare G
No Data